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Early phase clinic trails of T cells genetically engineered to express Chimeric Antigen Receptors (CAR) have 
been promising.  CD19-CAR T cells have been used successfully in a number of clinical trials to treat non-
Hodgkin’s lymphoma and acute lymphocytic leukemia (ALL) and clinical trials of GD2-CAR T cells for the 
treatment of osteosarcoma and neuroblastoma are underway.  Most CAR T cell manufacturing protocols make 
use of autologous peripheral blood mononuclear cell (PBMC) concentrates collected by apheresis, however, the 
lymphocyte-rich PBMC concentrates are also enriched for monocytes and contain small but variable quantities 
of red blood cells, platelets and neutrophils and prior to beginning CAR T cell manufacturing the PBMC 
concentrates are generally enriched for lymphocytes or CD3+ cells. 
 
We initially manufactured CD19- and GD2-CAR T cells using autologous PBMC concentrates enriched for T 
cells by selection with the anti-CD3/CD28 beads. These same anti-CD3/CD28 beads were used to stimulated T 
cell expansion. While the method was, in general, effective, we found that the quantities of GD2-CAR T cells 
produced were less than the quantities of CD19 CAR T cells produced. In addition, T cells from some patients 
failed to expand at all.  Further investigation found that the presence of large quantities of monocytes or 
granulocytes in some PBMC concentrates which was associated with poor in vitro CAR T cell expansion.   
 
Myeloid derived suppressor cells (MDSCs) that inhibit T cell proliferation are present in sarcoma and ALL 
patients. These MDSCs may have a monocyte or neutrophil phenotype. We hypothesized that MDSCs in the 
PBSC concentrates bound non-specifically to the anti-CD3/CD28 beads and more rigorous enrichment of the 
starting material for lymphocytes would improve CAR T cell yields and reduce the incidence of manufacturing 
failures.  We modified the T cell enrichment method to include a monocyte-depleting plastic adherence step. 
This change improved T cell expansion, but it was not completely effective at removing contaminating 
monocytes and granulocytes and did not completely eliminate manufacturing failures.  
 
To provide better depletion of monocytes and granulocytes we subjected PBMC concentrates to counter flow 
elutriation instrument. We manufactured 8 CD19- and 5 GD2-CAR T cell products from elutriated lymphocytes. 
All 13 CAR T cell manufacturing procedures yielded sufficient quantities of T cells to meet the dose criteria. The 
13 CAR T cell products contained 2,166±1,113 x106 CD3+ cells and 1,064±877 x106 transduced CD3+ T cells.  
The CAR T cell products manufactured from elutriated lymphocytes yielded significantly more CD3+ cells and 
transduced CD3+ cells than that of those manufactured from anti-CD3/CD28 bead selected and plastic 
adherence selected cells. 
 
These results show CAR T cell manufacturing yields are greater and more consistent when manufacturing is 
initiated with lymphocytes that have few contaminating myeloid cells. 
 
